Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies
Study Type: Treatment
Phase: I/II
NCTID: NCT06634589
Principal Investigator:
Marc Hoffmann
A Multicenter, Randomized, Double-blind, Placebo-Controlled, Phase III Study of Ficlatuzumab in Combination with Cetuximab in Participants with Recurrent or Metastatic R/M HPV-Negative Head and Neck Squamous Cell Carcinoma FIERCE-HN
Study Type: Treatment
Phase: III
NCTID: NCT06064877
Principal Investigator:
Prakash Neupane
A Randomized Controlled Trial using a Heuristic Tool To Improve Symptom Self-Management in Adolescents and Young Adults with Cancer
Study Type: Supportive Care
Phase: N/A
NCTID: NCT05958316
Principal Investigator:
Kristin Stegenga
A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation GVHD Prophy Rux PROGRESS IV
Study Type: Treatment
Phase: III
NCTID: NCT06615050
Principal Investigator:
Muhammad Umair Mushtaq
An International, Prospective, Open-label, Multi-center, Randomized Phase III Study comparing lutetium 177Lu vipivotide tetraxetan AAA617 versus Observation to delay castration or disease recurrence in adult male patients with prostate-specific membrane antigen PSMA positive Oligometastatic Prostate Cancer OMPC
Study Type: Treatment
Phase: III
NCTID: NCT05939414
Principal Investigator:
Xinglei Shen
A Phase I Study of Patient-Derived Multi-Tumor-Associated Antigen-Specific T-Cells MT-601 Administered to Patients with Relapsed or refractory Non-Hodgkin Lymphoma NHL [APOLLO]
Study Type: Treatment
Phase: I
NCTID: NCT05798897
Principal Investigator:
Haitham Abdelhakim
Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma CLL/SLL: EVOLVE CLL/SLL Study
Study Type: Treatment
Phase: III
NCTID: NCT04269902
Principal Investigator:
Marc Hoffmann
A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer Lung-MAP Screening Study
Study Type: Screening
Phase: III
NCTID: NCT03851445
Principal Investigator:
Anusha Chidharla
A Multicenter, Randomized, Open-Label, Phase III Trial of Trastuzumab Deruxtecan Enhertu� Plus Chemotherapy Plus or Minus Pembrolizumab Versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab as First-Line Treatment in Participants With Unresectable, Locally Advanced or Metastatic HER2-Positive Gastric Or Gastroesophageal Junction GEJ Cancer Destiny-Gastric05
Study Type: Treatment
Phase: III
NCTID: NCT06731478
Principal Investigator:
Weijing Sun
A Phase I/II, Open Label, Single Arm, Two Part Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti Tumor Activity of glofitamab in Combination with Chemoimmunotherapy in Pediatric and Young Adult Participants with Relapsed/Refractory Mature B-cell Non-Hodgkin Lymphoma
Study Type: Treatment
Phase: I/II
NCTID: NCT05533775
Principal Investigator:
Kevin Ginn